Indeed, in the study conducted by Jane et al. (2006[17]), Western blot analysis demonstrated that sorafenib affected phosphorylation of ERK and AKT kinases in glioma cells, and this effect was further potentiated by rottlerin. The gene discussed is AKT1; the disease is central nervous system cancer.